AI in health care
Searching the Web
AI in healthcare 2025 2026 latest developments clinical applications
Searching PubMed
"artificial intelligence"[MeSH Terms] AND "delivery of health care"[MeSH Terms]
Here is a structured overview of AI in healthcare as of mid-2026, drawing on recent peer-reviewed evidence and current developments:
AI in Healthcare: A Current Overview
1. Clinical Documentation - AI Scribes
One of the fastest-adopted applications is ambient AI scribing - AI listens to clinician-patient conversations and auto-generates clinical notes. A 2025 systematic review in Applied Clinical Informatics (PMID: 40306686) found that AI scribes reduce documentation burden and physician burnout, though integration challenges and accuracy concerns in complex cases remain. Major platforms include Nuance DAX, Suki, and Ambience Healthcare.
2. Large Language Models (LLMs) in Clinical Practice
A JAMA 2025 systematic review (PMID: 39405325) evaluated LLM applications across healthcare and found strong performance in clinical question-answering, medical education, and patient communication - but flagged inconsistent accuracy, hallucinations, and lack of real-world validation as key concerns. An umbrella review in Journal of Biomedical Science (PMID: 40335969) confirmed ChatGPT and similar models are being studied for diagnosis support, health education, mental health triaging, and coding/billing.
3. Medical Imaging & Diagnostics
AI in radiology, pathology, and ophthalmology is arguably the most mature area:
- Radiology: AI tools detect lung nodules, fractures, intracranial hemorrhage, and breast cancer on mammography with performance rivaling radiologists in controlled studies.
- Pathology: Digital pathology AI can classify tumors and predict molecular subtypes from histology slides.
- Ophthalmology: FDA-cleared AI (e.g., IDx-DR) autonomously screens for diabetic retinopathy without a specialist.
- GE HealthCare (June 2026) is actively expanding AI-enabled nuclear medicine workflows at the SNMMI Annual Meeting, integrating AI with PET imaging and theranostics.
4. Chronic Disease Management & Chatbots
A 2024 systematic review (PMID: 38466897) found AI-powered chatbots improve self-management behaviors in chronic diseases (diabetes, hypertension, COPD) by delivering personalized coaching, medication reminders, and symptom monitoring. Limitations include engagement drop-off and lack of long-term outcome data.
5. Nursing & Patient Outcomes
A 2025 systematic review in Journal of Nursing Scholarship (PMID: 40836587) found AI applications in nursing - predictive sepsis alerts, fall risk scoring, pressure injury detection - are associated with improved patient safety outcomes, though nurse training and workflow integration remain barriers.
6. Drug Discovery & Development
AI is dramatically shortening the drug discovery pipeline:
- AlphaFold (DeepMind) has predicted structures for virtually every known protein, transforming target identification.
- AI-designed molecules have entered clinical trials (e.g., Insilico Medicine's INS018_055 for IPF is in Phase II).
- IQVIA and other CROs are embedding "Healthcare-grade AI" into clinical trial design, patient recruitment, and pharmacovigilance.
7. Administrative AI
- Revenue cycle management: AI automates prior authorizations, coding, and claim denials. A KLAS 2026 report notes that while AI-driven clinical decision support is increasingly discussed, only ~40% of deep adopters are actively using archived data for AI-driven analytics in real production workflows.
- Scheduling & triage: NLP tools route patient messages and prioritize callbacks.
Key Challenges
| Challenge | Detail |
|---|---|
| Bias & equity | Models trained on non-representative data can perform worse for minority populations |
| Hallucinations | LLMs generate plausible but incorrect clinical information |
| Regulatory | FDA 510(k)/De Novo pathways for AI/ML-based SaMD (Software as Medical Device) are evolving |
| Privacy | HIPAA compliance, data governance, and de-identification requirements |
| Workflow integration | EHR interoperability and clinician adoption remain practical barriers |
| Accountability | Liability when AI contributes to a diagnostic or treatment error |
Bottom Line
AI in healthcare is no longer experimental in many domains - it is actively deployed in documentation, imaging, risk scoring, and patient engagement. The highest-quality recent evidence (JAMA 2025, JNSP 2025) supports real benefit but emphasizes the need for rigorous real-world validation, equity audits, and transparent regulatory frameworks before broader clinical reliance. The next 2-3 years will likely see AI move from assistive to more autonomous roles in narrow, well-defined tasks.
This is a shared conversation. Sign in to Orris to start your own chat.